MedPath

A Clinical Trial of a Hemp-Derived Cannabidiol Product for Anxiety

Phase 2
Terminated
Conditions
Anxiety
Registration Number
NCT04286594
Lead Sponsor
Mclean Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Terminated
Sex
All
Target Recruitment
15
Inclusion Criteria

Inclusion Criteria:<br><br> - Subject has provided informed consent<br><br> - Subject is 18 or older<br><br> - Subject is a native English speaker or acquired English prior to age 5<br><br> - Subject endorses moderate or severe anxiety at the screening visit<br><br>Exclusion Criteria:<br><br> - Non-native English speakers<br><br> - Estimated IQ < 75<br><br> - Current substance abuse/dependence, psychotic disorder, bipolar disorder, or an<br> eating disorder<br><br> - A history of head injury or loss of consciousness greater than 5 minutes<br><br> - Currently uses marijuana or cannabinoid-based products more frequently than 1x/month<br><br> - Female subjects will be excluded if they have a positive urine pregnancy test, or if<br> they are currently breastfeeding<br><br> - Presence of a serious medical illness, including liver or kidney disease, or<br> neurological disorder<br><br> - Allergy to coconut oil<br><br> - Current use of valproate<br><br> - Additional exclusions related to MR imaging, including claustrophobia, metal<br> implanted within the body, etc.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath